# A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

> **NCT02930655** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Lucerastat
- **DRUG:** Enzyme replacement therapy (ERT)

## Key facts

- **NCT ID:** NCT02930655
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-01
- **Primary completion:** 2016-02-01
- **Final completion:** 2016-02-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02930655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02930655, "A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02930655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*